Biotech's 10 Biggest PR Disasters of 2012
By GMWatch,
GMWatch
| 12. 31. 2012
The 10 biggest GMO PR disasters of 2012
[For links, please refer to the original article here]
2012 was the year the lights came up on the biotech industry. Its claims, its tactics and its products all came under scrutiny and some of its biggest PR fairytales bit the dust. Here are some prime examples.
1. Fleeing Europe: The biotech bubble needs to appear to be constantly expanding but in early 2012 came the news that the GM and chemicals giant BASF was pulling its GM division out of Europe because it was facing opposition "from the majority of consumers, farmers and politicians." BASF also announced it was stopping the commercialization of its GM Amflora potato, one of only two GM crops authorized for cultivation in the European Union. The crop had been a commercial flop. The industry's only other crop grown in Europe, Monsanto's Mon810 GM maize, continued to face bans in a number of countries including France and Germany. Even GM crop trials are in decline and with BASF quitting Europe they're expected to decline still further...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...